导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 9.88% | 732/4773 |
| 近一周 | -2.35% | 1899/5462 |
| 近一月 | -8.83% | 4410/5421 |
| 近一季 | -10.82% | 3595/5209 |
| 近半年 | 7.61% | 612/4920 |
| 近一年 | 12.12% | 868/4366 |
| 近两年 | 90.12% | 686/2954 |
| 近三年 | 48.10% | 567/2253 |
| 成立以来 | 95.55% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.86% 2932/4961 |
43.12% 714/5312 |
- - |
- - |
| 2025 | 37.03% 917/4813 |
4.02% 1005/3635 |
1.44% 2329/4076 |
34.56% 1011/4524 |
-3.49% 3284/4813 |
| 2024 | 4.13% 1890/3463 |
-5.60% 1932/2808 |
-5.06% 1630/3014 |
15.28% 1763/3129 |
0.79% 1167/3463 |
| 2023 | -8.53% 1022/2656 |
12.70% 285/2280 |
-3.86% 934/2385 |
-10.64% 2012/2515 |
-5.52% 1381/2655 |
| 2022 | -25.03% 1284/2207 |
-18.73% 1386/1919 |
4.78% 977/2016 |
-15.80% 1345/2113 |
4.57% 535/2208 |
| 2021 | 13.23% 362/1822 |
-5.54% 931/1255 |
19.68% 156/1330 |
-5.64% 838/1466 |
6.14% 234/1822 |
| 2020 | 71.58% 64/1250 |
4.61% 66/1028 |
23.67% 189/1067 |
12.22% 399/1164 |
18.19% 99/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 申万菱信中证研发创新100ETF联接A VS. 长安沪深300非周期A(740101) |